News Moderna agrees $950m settlement of mRNA jab litigation Moderna's settlement of patent litigation with Arbutus and Genevant over technology used in its Spikevax COVID vaccine could reach up to $2.25bn.
News Moderna closes on EU approval for combined flu/COVID jab Moderna's combined vaccine for both flu and COVID-19 has been recommended for approval in the EU, after being knocked back in the US.
News Bayer's Monsanto sues mRNA COVID-19 vaccine makers Lawsuits filed by Bayer in the US are seeking damages and royalties on sales of COVID-19 shots sold by Pfizer/BioNTech, Moderna, and J&J.
News Investor seeks sale of Novavax after poor COVID jab sales Investor Shah Capital has called on Novavax's board to put the company up for sale, citing a "litany of missteps" at the vaccine developer.
News COVID-19 vaccine support reined back by ACIP The CDC's vaccine committee reduced some support for COVID-19 vaccines, but did not go as far as some might have feared in limiting access.
News Moderna cuts staff amid operating 'uncertainty' Moderna will cut another 10% of its workforce as it tries to trim $1.5 billion off its annual costs by 2027.
News MSD rumoured to be nearing $6bn play for Terns Pharma MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff is reported to be continuing with a $6bn bid to acquire Terns Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.